Nucleate Podcast

Latest Episodes:

AI, Amino Acids, and Aging: Inside Retro Biosciences | Joe Betts-Lacroix Oct 06, 2026

Show notes

Here's a segment breakdown with timestamps:

[0:58 – 1:43] Introduction & Career Background
[1:44 – 7:04] Regulation & the "Daughter Test"
[7:05 – 13:15] From Tech to Biotech: The Pivot
[13:16 – 21:35] AI at Retro & the OpenAI Partnership
[21:36 – 25:20] The 10-Year Lifespan Mission Explained
[25:21 – 33:20] Lead Program: Alzheimer's & Autophagy
[33:21 – 40:00] Broader Pipeline & Company Philosophy
[40:01 – 45:50] Cell Replacement vs. Cell Rejuvenation
[45:51 – 51:55] AI-Designed Transcription Factors & Partial Reprogramming
[51:56 – 54:03] On Biohackers & the DTC Longevity Industry
[54:04 – 56:02] "Whose Lives Are We Extending?" & Closing Thoughts

Building, Breaking, and Rebuilding Biotech | Deborah Dunsire Sep 29, 2026

Show notes

See the episode breakdown with time stamps below:

0:00 – Cold open: the "unexpected collaboration" teaser

0:35 – Growing up in Zimbabwe and an unplanned path into medicine

5:41 – The "9-month detour" into pharma that turned into a 30-year career

20:01 – Learning to lead: finance, business instincts, and the power of asking questions

23:55 – Launching Gleevec — and the patients who make it all worth it

31:21 – Taking the leap: becoming CEO of Millennium and betting big on Velcade

39:41 – Layoffs done right: dignity, trust, and the "milk mustache" story

49:57 – Inside the $8.8B Takeda acquisition and navigating a clash of cultures

1:08:30 – Failure and resilience: Forum Therapeutics and a rocky start at Lundbeck

1:22:48 – The $2.2B Alder bet, boardroom battles over share classes, and closing lessons on culture (plus the rapid-fire round)

From Nobel-Winning Discovery to Co-Founding Biogen | Phil Sharp Sep 24, 2026

Show notes

Time Stamps:

(3:10) Phillip’s background and how it shaped his character
(6:13) What first sparked his passion for science
(9:15) What inspired his PhD journey
(17:35) The discovery of restriction enzymes and DNA synthesis, concerns about DNA manipulation and how NIH guidelines came to be
(25:00) How to communicate your science and translate that knowledge for public benefit
(33:17 The discovery of RNA splicing
(48:40) The founding of Alnylam
(58:10) The creation of the biotech industry
(1:03:30) How to keep up with the latest science and important trends to watch
(1:12:55) Advice for founders looking to launch their own companies
(1:16:47) Traits to look for in a mentor and what makes a strong mentor-mentee relationship
(1:19:53) Critical pieces of company culture that drive success
(1:24:59) Quick fire questions

Zero to One: The Precision Medicine Playbook for Cardiac Disease | Nolan Townsend Lexeo Therapeutics Sep 17, 2026

Show notes

Here is a segment breakdown of the episode:
0:00–1:42 — Intro and guest background: host frames the episode and introduces Nolan Townsend's career across Wall Street, Pfizer, and Lexeo.
1:42–3:21 — From finance to healthcare: what drew Nolan into life sciences and the appeal of the industry's complexity.
3:21–10:13 — Pfizer's international roles: P&L leadership in Korea, Ukraine, and beyond, and how working across health systems and cultures shaped him.
10:14–19:00 — Rare disease leadership at Pfizer: the tafamidis/TTR amyloid cardiomyopathy story and its influence on Lexeo's founding thesis.
19:00–24:16 — Founding Lexeo in January 2020: the decision to leave Pfizer, launching amid COVID, and building a team remotely.
24:19–37:39 — Lexeo's scientific thesis: applying oncology's precision-medicine model to cardiac disease, the lead pipeline (Friedreich's ataxia, arrhythmogenic cardiomyopathy), and the Alzheimer's/APOE program and why it was deprioritized.
37:39–47:20 — Fundraising strategy: de-risking the story, the cooled IPO market, tranche financing, and advice for founders raising seed/Series A rounds.
47:20–50:00 — Mentors: Ron Crystal, Steve Altschuler, Ted Love, and the lessons drawn from each.
50:23–56:04 — Rapid-fire questions: influential book (Clayton Christensen), views on what's holding back broader use of gene therapy, and the most underrated CEO skill.
56:04–57:33 — Closing question (life outside biotech) and sign-off.

Refusing to give up on an Oncology Breakthrough | Dana T. Aftab, Exelixis Sep 10, 2026

Show notes

Time Stamps:

0:45 Introduction to Dana Aftab and what sparked his passion for science

6:39 His Ph.D. experience at Yale that led to a breakthrough in compound screening

16:15 Why that soured him on biotech and what ultimately drew him back in

24:33 Navigating the transition into industry by trusting his gut

30:09 The Exelixis-MetaXen acquisition

37:18 Taking the lead as a helping guide to younger scientist

41:00 What does it take to be a good manager

48:45 Discovery and development of CABOMETYX® (cabozantinib)

57:15 How differentiating clinical data changed the trajectory of Exelixis

1:00:34 Navigating the restructuring process

1:07:13 Rebuilding the Exelixis team

1:11:26 His return to science

1:13:30 Advice for founders on what makes a strong potential partner

1:20:07 Quick fire questions

Using Philanthropy to Drive Cures for Multiple Myeloma | Stephanie Oestreich, PhD MMRF Jul 23, 2026

Show notes

(0:53) Introduction to Stephanie’s passion for science and her career transition from research to business
(8:40) Key foundational business development skills
(13:06) What investors look for when evaluating early stage technology
(14:37) The story behind Gleevec and its commercialization journey
(19:36) Long term planning for early career scientists
(24:39) Differences between U.S. and European ecosystems across pharma and biotech
(30:30) Introduction to the Multiple Myeloma Research Foundation
(36:23) How in vivo CAR-T and cell therapy are advancing multiple myeloma care
(42:08) Advice for entrepreneurs interested in the Nucleate Activator program
(54:18) How can startup founders best position themselves in a competitive landscape
(1:03:10) Quick fire questions

Translating Science into Patient Impact with Kendra Rose Jun 23, 2026

Show notes

Time Stamps:

(2:37) Introduction to Kendra’s professional journey and how she found her path into science

(7:30) Understanding the consumer mindset and patient perspectives

(13:05) Key parameters that shape important decisions

(17:45) Core lessons on bridging the gap between science and business

(25:30) Introduction to Bayer and Kendra’s role as Senior Vice President of Business Development and Licensing

(29:46) Latest trends shaping healthcare research, education, and innovation

(38:59) How to establish credibility as an entrepreneur in a competitive market

(41:28) Inside the Bayer Co.Lab incubator ecosystem and the support it offers

(50:37) Tips for early-career scientists interested in making a pivot from the lab to business

(57:09) Do you really need a Ph.D. to break into pharma?

(1:00:01) Quick fire questions

Leading Mission-Driven Biotechs | Jodie Morrison, CEO of Q32 Bio Jun 04, 2026

Show notes

Time Stamps

01:42: Jodie’s early interest in science and the defining moment

03:31: Starting from the bottom in clinical research shaped her leadership style as a CEO

08:32: How she joined Q32 Bio and then took them public

10:11: Jodie’s inspiration to get involved with challenging companies

11:42: The emotional reward of biotech: the long hours are worthwhile to save lives

13:46: Navigating challenging situations

15:10: Q32 Bio's focus on autoimmune disorders

19:59: The origins of the CEO Forum

27:54: The "lonely" nature of being a CEO and the importance of community

30:54: Philosophy on female leadership: “lift while we climb”

34:54: How AI is involved in biotech

43:24: Navigating challenging capital markets: focus on “killer experiments” that investors want

46:47: Balancing "ethical obligation" to employees with their "fiduciary responsibility" to investors

49:56: How layoffs are “heartbreaking” but necessary to preserve capital for future drug development

56:30: The future of biotech is "cautious optimism" but needed

1:00:06: Initiatives among leaders to heal the misconception of science

01:05:01: Rapid Fire questions

From Genomics to Deal-Making: How Science Becomes a Company | Laurence Reid, Biotech Entrepreneur Mar 24, 2026

Show notes

Time Stamps

[00:00] Laurence explains biotech to a five-year-old

[01:55] Early life in the UK and first steps toward biotech

[02:47] How The Double Helix and Celltech shaped his path

[07:15] Moving from bench science to Cell and a wider view of research

[13:04] Learning business development at Millennium

[15:30] Why relationships matter in biotech deals

[17:43] How Millennium changed from platform company to drug developer

[28:01] Joining Alnylam and building around RNAi

[39:19] Becoming a CEO at Warp Drive Bio

[44:36] Novel antibiotics, molecular glues, and the RevMed merger

[52:07] What founders should know about building to make a lasting impact

[54:50] Joining Decibel during restructuring and COVID

[58:55] Rebuilding culture and sharpening strategy

[1:09:49] Why Decibel focused on gene therapy for the inner ear

[1:25:05] Advice for founders raising money in a hard market

Negotiating Intellectual Property, Staying Focused, and Making the Most of Mentors with Michal Preminger, Board Member at MassBio Mar 10, 2026

Show notes

Time Stamps

(0:55) Introduction to Michal’s background and her professional journey

(7:58) How Michal leveraged tech skills to break into computational biology

(13:15) Her experience at Compugen working on early AI-enabled drug discovery

(19:52) Challenges startup founders face and strategies to overcome them

(25:19) Michal’s personal experience as a founder at Anima Biotech

(32:52) Resources available at academic institutions to support startups

(40:15) How to successfully negotiate as a scientific founder

(46:51) Michal’s role at Johnson & Johnson

(53:13) Introduction to MassBio and their purpose

(58:35) Advice on networking and how to form meaningful partnerships

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected